Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,288 questions · 3,354 findings · 516 reviews · Headline outcomes only

No studies found 720 · 21.5%GRADE not reported 164 · 4.9%Very low 950 · 28.3%Low 932 · 27.8%Moderate 434 · 12.9%High 154 · 4.6%

Febuxostat 120 mg/day vs placebo

Serum uric acid <6.0 mg/dL at final visit · patients with chronic cout

Febuxostat 120 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs placebo

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 40 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs allopurinol

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs allopurinol

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 80 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (low certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs allopurinol

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 120 mg/day probably leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs placebo

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 80 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).

1 finding from 1 review

Intervention not reported

Utilisation of research (Thailand) (for six obstetric practices: social support during labour, magnesium sulphate for eclampsia, corticosteroids to women with preterm birth, selective episiotomy, antibiotic use at caesarean section and vacuum extr... · Healthcare decision makers, health system managers or policy makers
1 finding from 1 review

Intervention not reported

Utilisation of research (Mexico) (for six obstetric practices: social support during labour, magnesium sulphate for eclampsia, corticosteroids to women with preterm birth, selective episiotomy, antibiotic use at caesarean section and vacuum extrac... · Healthcare decision makers, health system managers or policy makers
1 finding from 1 review

Intervention not reported

Utilisation of research (4 obstetric practices: use of polyglycolic acid sutures, ventouse for instrumental delivery, prophylactic antibiotics in caesarean section, and prophylactic corticosteroids in preterm deliveries).2 · Healthcare decision makers, health system managers or policy makers
1 finding from 1 review

Vaccination vs placebo

Persistence of PHN among all subjects a numerical rating scale for pain1 · people at risk for postherpetic neuralgia

Vaccination leads to lower persistence of PHN among all subjects a numerical rating scale for… compared with placebo (high certainty).

1 finding from 1 review

Vaccination vs placebo

Persistence of PHN among subjects developing herpes zoster a numerical rating scale for pain1 · people at risk for postherpetic neuralgia

Vaccination showed no clear difference in persistence of PHN among subjects developing herpes zoster a… compared with placebo (moderate certainty).

1 finding from 1 review

Corticosteroids vs placebo

Caloric extent of recovery (improvement as a % in lateralisation of electronystagmography on caloric testing) · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)
2 findings from 1 review

Corticosteroids vs placebo

Complete caloric recovery · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)

Corticosteroids may leads to higher complete caloric recovery compared with placebo (low certainty).

2 findings from 1 review

Intervention not reported

Functional status (generic) Sickness Impact Profile (0‐136) short‐term · adults with chronic low‐back pain
1 finding from 1 review

Intervention not reported

Functional status (generic) Sickness Impact Profile (0‐136) intermediate‐term · adults with chronic low‐back pain
1 finding from 1 review

Intervention not reported

Functional status (generic) Sickness Impact Profile (0‐136) long‐term · adults with chronic low‐back pain
1 finding from 1 review

Intervention not reported

Functional status (generic) various scales short‐term · adults with chronic low‐back pain
1 finding from 1 review

Intervention not reported

Functional status (generic) various scales intermediate‐term · adults with chronic low‐back pain
1 finding from 1 review

Intervention not reported

Functional status (generic) various scales long‐term · adults with chronic low‐back pain
1 finding from 1 review